Impact of Age and Associated Comorbidities on Survival Outcomes in Patients with Advanced Breast Cancer Treated with Palbociclib, Ribociclib, and Abemaciclib

Overview

This study investigates the survival outcomes of older patients with advanced breast cancer treated with CDK inhibitors.

Background

Breast cancer is the most common malignancy in women, with a significant incidence in older adults. Older patients often face worse survival outcomes due to age-related comorbidities and underrepresentation in clinical trials.

Data Highlights

No numerical data available in the source material.

Key Findings

• Older adults with breast cancer often have a higher prevalence of comorbidities impacting treatment outcomes.
• CDK inhibitors have transformed the management of hormone receptor-positive advanced breast cancer.
• Real-world data indicate that older patients may experience inferior overall survival compared to younger patients.
• There is a noted underrepresentation of older adults in clinical trials for cancer treatments.
• Age-related comorbidities may influence treatment tolerance and prognosis in older breast cancer patients.

Clinical Implications

Clinicians should consider the challenges faced by older breast cancer patients, including comorbidities that may affect treatment decisions.

Conclusion

The study highlights the importance of considering health profiles and comorbidities in older patients with advanced breast cancer.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. The ASCO Post, 2019 -- Landmark Studies Show Clear Overall Survival Benefit for CDK4/6 Inhibitors in Advanced Breast Cancer
4. ESMO, 2023 -- ESMO Clinical Practice Guidelines for Breast Cancer
5. The ASCO Post — No Benefit for Adjuvant Palbociclib in Stage IIA Breast Cancer: Analysis From the PALLAS Trial
6. NCCN Guidelines for Oncology
7. ESMO_2023_BreastCancer.pdf
8. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer - PMC
9. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025 - PMC
10. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - PubMed
11. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial - PMC
12. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer - PMC
13. Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2 | JCO Oncology Advances
14. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3 - PubMed
15. CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials - PubMed
16. Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in elderly women with HR+/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis - PubMed
17. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials - ScienceDirect
18. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials - PMC
19. Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study - PubMed
20. Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study - PMC
21. Frontiers | Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review
22. Age-stratified toxicity patterns of CDK4/6 inhibitors in older women with breast cancer: Disproportionality analysis from the FAERS database - ScienceDirect
23. Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients - PubMed